Jagsonpal Pharmaceuticals Limited has successfully approved its comprehensive share buyback proposal during the board meeting held on March 12, 2026. The pharmaceutical company's board has decided to repurchase up to 16 lakh equity shares at ₹250 per share through the tender offer route, with the total buyback value reaching ₹40 crores. The buyback price represents a premium of 40% to the current market price.

Buyback Approval and Structure

The board meeting, conducted under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, resulted in formal approval of the buyback proposal. The decision encompasses all regulatory and procedural aspects required for implementation, subject to shareholder approval and other statutory approvals.

Financial Rationale and Cash Position

The company operates with an asset-light business model requiring minimal capital for scaling operations. Between FY22 to FY25, Jagsonpal added over ₹142 crores of free cash despite increased dividends and ₹95 crores deployed for acquisitions. As of December 31, 2025, the company maintains free cash of ₹176 crores.

Professional Advisory and Compliance Framework

The company has appointed Centrum Capital Limited, a SEBI registered Merchant Banker, as the Manager to the Buyback. A dedicated "Buyback Committee" has been constituted with delegated powers, including authority to fix the record date and undertake necessary actions for the proposed buyback.

Shareholding Impact and Promoter Strategy

A significant aspect of this buyback is the promoters' decision to abstain from participation entirely. This strategic choice ensures buyback benefits are concentrated among non-promoter shareholders, potentially increasing ownership concentration for participating public investors. Managing Director Manish Gupta emphasized the company's commitment to enhancing shareholder value and optimizing capital structure.

*Indicative figures assuming full buyback of 16 lakh shares

Implementation Timeline and Next Steps

The board meeting, which commenced at 1:00 PM and concluded at 1:45 PM, marks the formal approval stage of the buyback process. The company will separately intimate details regarding the postal ballot for seeking shareholder approval. The buyback excludes expenses such as brokerage costs, fees, securities transaction tax, and other incidental expenses from the maximum offer size calculation.

Jagsonpal Pharmaceuticals Limited has announced a significant employee stock option grant, with its board committee approving the allocation of 11,52,500 stock options to employees under the company's established ESOP framework.

Board Committee Approval

The Nomination and Remuneration Committee of the Board of Directors approved the employee stock option grant during their meeting held on March 09, 2026. The decision represents a substantial allocation under the Jagsonpal Pharmaceuticals Limited Employees Stock Option Plan, 2022.

ESOP Grant Details

The key parameters of the stock option grant are structured as follows:

Vesting Structure

The granted stock options will follow a systematic vesting schedule designed to retain talent over multiple years. The options are convertible into an equivalent number of equity shares of Rs. 2.00 each. The vesting structure includes:

• Vesting Period: 4 equal annual tranches
• Commencement: First anniversary of the grant date
• Annual Allocation: Approximately 2,88,125 options per tranche

Corporate Communication

The company has formally communicated this development to both major stock exchanges where its shares are listed. Company Secretary and Compliance Officer Pratham Rawal signed the intimation letter, ensuring regulatory compliance and transparency with stakeholders.

This ESOP grant reflects the company's commitment to employee retention and alignment of workforce interests with long-term corporate performance objectives.